Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs
Author(s): Frankum James, Ramsay Dale, Das Nandita G, Das Sudip K
Issue: Mar/Apr 2004 - Overview of USP Chapter <797>
View All Articles in Issue
Page(s): 101-105
Download in electronic PDF format for $75
Abstract: The authors begin with a rationalization for a vehicle such as Pluronic lecithin organogel: the need to find a method of administering analgesics and pain medications for local pain relief that minimizes systemic side effects. They then discuss the mechanism of pain, drugs used to treat pain, Pluronic lecithin organogel as a vehicle for delivering topical analgesia, the ability of Pluronic lecithin organogel to enhance bioavailability of drugs, clinical studies with topical nonsteroidal anti-inflammatory drugs, pharmacokinetics of nonsteroidal anti-inflammatory drugs following topical application, side effects, and instructions for use. They conclude that Pluronic lecithin organogel provides a topical vehicle base for delivery of analgesic drugs that can supplant injection or oral administration, with the advantages of significant reduction of severe side effects, increased patient compliance and increase of potential analgesic effects at the painful site. They note that this dosage form can have side effects such as local irritation and may not be appropriate for use with all drugs. Despite these reservations, the authors suggest that Pluronic lecithin organogel appears to be effective as an alternative method for delivery of pain relief, for both patient and practitioner.
Related Keywords:
Anti-inflammatory drugs, PLO as vehicle for, Nonsteroidal anti-inflammatory drugs, in PLO, NSAIDs, in PLO, PLO, for anti-inflammatory drugs, Pluronic lecithin organogel, and anti-inflammatory drugs, as vehicle for
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs
Frankum James, Ramsay Dale, Das Nandita G, Das Sudip K
|
Mar/Apr 2004
Pg. 101-105
|
The History of Pluronic Lecithin Organogel: An Interview With Marty Jones, BSPharm, FACA, FIACP
Allen Loyd V Jr
|
May/Jun 2003
Pg. 180-183
|
Enhancement of Skin Penetration of Nonsteroidal Anti-Inflammatory Drugs from Extemporaneously Compounded Topical-Gel Formulations
Goodwin Donald A, Fuhram L Clifton
|
Nov/Dec 1999
Pg. 496-500
|
Ketoprofen 10% in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Jan/Feb 2019
Pg. 52
|
Veterinary Antibiotic/Antifungal/Anti-Inflammatory Anesthetic Otic Drop
Allen Loyd V Jr
|
May/Jun 1999
Pg. 225
|
Veterinary Antibiotic/Antifungal/Anti-Inflammatory Anesthetic Otic Drops
Hinkle Amanda R, Newton Gail D
|
May/Jun 2004
Pg. 185
|
The Use of Pluronic Lecithin Organogels in the Transdermal Delivery of Drugs
Bramwell Bethany L, Williams LaVonn A
|
Jan/Feb 2012
Pg. 62-63
|
Preparation and In Vitro Evaluation of a Pluronic Lecithin Organogel Containing Ricinoleic Acid for Transdermal Delivery
Boddu Sai HS, Bonam Sindhu Prabha, Wei Yangjie, Alexander Kenneth
|
May/Jun 2014
Pg. 256-261
|
Transdermal Administration of Anti-inflammatory Medications in Sports Injuries: Use of Iontophoresis and Phonophoresis to Enhance Delivery
Heim Bob
|
Jan/Feb 2006
Pg. 14-18
View Sample |
BHR in PLO Gel (Benadryl, Haldol, and Reglan in Pluronic Lecithin Organogel)
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 322
|
Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Hong Eun Ji, Sumanasekera Wasana, Le Uyen Minh
|
Jan/Feb 2022
Pg. 65-71
|
Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study
Glisson James K, Wood Rebecca L, Kyle Patrick B, Cleary John D
|
May/Jun 2005
Pg. 242-246
|
Effect of Formulation pH on Transdermal Penetration of Antiemetics Formulated in Poloxamer Lecithin Organogel
Woodall Rachel, Arnold John J, McKay Doug, Abill C Scott
|
May/Jun 2013
Pg. 247-253
|
Ketoprofen 10% in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Mar/Apr 2019
Pg. 150
|
Ketoprofen 10%, Ibuprofen 10%, Cyclobenzaprine Hydrochloride 2%, and Piroxicam 2% in Pluronic Lecithin Organogel Gel
Allen Loyd V Jr
|
May/Jun 2011
Pg. 245
|
Amitriptyline Hydrochloride 2%, Baclofen 5%, Ketamine Hydrochloride 5%, Ketoprofen 10% in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Nov/Dec 2010
Pg. 512
|
Baclofen 5%, Capcaicin 0.075%, Ketoprofen 10%, and Tetracaine 2% in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Nov/Dec 2010
Pg. 513
|
Baclofen 5%, Gabapentin 5%, Ketoprofen 10%, and Lidocaine 5% in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Nov/Dec 2010
Pg. 514
|
Indomethacin 2% in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Nov/Dec 2008
Pg. 543
|
Cyclobenzaprine Hydrochloride 0.5% and Diclofenac Sodium 3% in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Nov/Dec 2008
Pg. 540
|
Return to Top |